Weight Loss Drugs arent “the answer”
Sheffield DPH
FEBRUARY 21, 2024
Before you read this, you must read Phil’s New Statesman article on GLP1 agonists. Do Health Economics 101 and read the TA, section 4 esp the discrepancy between manufacturers model assumptions vs committee central base case 3. likely to widen health inequalities. Opportunity cost ?? what are we cutting, not investing in.
40 
Let's personalize your content